000009295 001__ 9295
000009295 005__ 20240124114320.0
000009295 0247_ $$2DOI$$a10.6083/h989r4099
000009295 037__ $$aIR
000009295 245__ $$aIn silico assessment of somatic mutation generated T cell epitopes in various subsets of acute myeloid leukemia
000009295 260__ $$bOregon Health & Science University
000009295 269__ $$a2021
000009295 336__ $$aArticle
000009295 502__ $$bM.S.
000009295 520__ $$aDespite decades of conventional chemotherapy, the prognosis for patients with acute myeloid leukemia (AML) remains dismal, with 75% of patients succumbing to their disease within 5 years of diagnosis. Recent advances in cancer therapy have turned to the immune system for specific targeting and clearance of tumors. However, to date, there is not a comprehensive understanding of the neoepitope landscape in AML that could be used in the next generation of immunotherapies. In this study, genomic data from 562 patients (cohort: Beat AML program, Oregon Health & Science University) were analyzed computationally to identify tumor variants, altered mRNA sequences of variants, and HLA-type. Using a computational pipeline and algorithm (neoepiscope), we were able to predict 8-11 amino acid peptide sequences (aka: epitopes) from DNA-seq of complementary tumor and normal patient samples which consider germline context and the potential for co-occurrence of two or more somatic variants on the same mRNA transcript.
000009295 650__ $$aComputational Biology$$031511
000009295 6531_ $$abioinformatics
000009295 6531_ $$acancer
000009295 6531_ $$aimmunology
000009295 691__ $$aSchool of Medicine$$041369
000009295 7001_ $$aLoo, Christopher P.$$uOregon Health and Science University$$1https://orcid.org/0000-0002-5302-8774$$041354
000009295 8564_ $$9ebcf2efe-9fa5-4331-bc24-a27abe15302c$$s1229181$$uhttps://digitalcollections.ohsu.edu/record/9295/files/Loo.Christopher.2021.pdf
000009295 905__ $$a/rest/prod/h9/89/r4/09/h989r4099
000009295 909CO $$ooai:digitalcollections.ohsu.edu:9295$$pstudent-work
000009295 980__ $$aStudent Work